Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Airbnb, Inc. (ABNB) vs ADMA Biologics Inc (ADMA) Price & Performance

Airbnb, Inc.Trade
ADMA Biologics IncTrade

Price performance (Past 24H)

Key statistics

Airbnb, Inc. vs ADMA Biologics Inc — how do they compare? Airbnb, Inc. trades at $181.44 (market cap $110.60B), while ADMA Biologics Inc trades at $9.85 (market cap $2.18B). The key difference: Airbnb, Inc. is far larger — about 50.7× ADMA Biologics Inc's market cap, and Airbnb, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ABNBADMA
Market Cap
$110.60B$2.18B
Sector
Consumer CyclicalHealth
52-Week High
$184.70$20.38
52-Week Low
$111.54$7.60
Enterprise Value
$101.02B$2.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Airbnb, Inc.

Airbnb (ABNB) is trading at $178.07, up 17.43% with strong momentum after Q2 2026 earnings beat expectations. The stock is approaching four-year highs with bullish technical indicators and positive analyst sentiment. Revenue growth accelerated to $12.24B in 2025 with robust 82.9% gross margins, though recent quarters showed mixed earnings performance with two misses and one beat.

Outlook remains positive with AI-driven growth initiatives and expanding service offerings, but elevated valuation multiples (P/E 40.66) and competitive pressures present risks. Analyst consensus leans bullish with 46.7% buy ratings and $173.26 price target, though current price exceeds consensus target by 2.8%.

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Airbnb, Inc.

Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.

Read more on ABNB

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA